Everest Medicines Limited (1952.HK) HKSE
29.72
-0.64(-2.11%)
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
Everest Medicines Limited
Sector
Healthcare
Industry
Biotechnology
Employees
665
First IPO Date
October 09, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Yongqing Luo | Chief Executive Officer & Executive Director | 16,882 | 1970 |
| Yifang Wu | Executive Chairman of the Board | 10,520 | 1969 |
| Ying Woo | Chief Financial Officer, President & Executive Director | 17,245 | 1973 |
| King Hang Yeung | Joint Company Secretary | 0 | 1992 |
| Wei Yang | Chief Scientific Officer | 0 | 1970 |
| Xu Liang | Chief Product Officer | 0 | 1969 |
| Jason Brown | Chief Business Officer | 0 | 1973 |
| Wenjun Liu | Co-President & Chief Commercial Officer | 0 | 1990 |
| Chonggang Xu | Chief Operations Officer | 0 | 1969 |
| Yee Wa Lau | Joint Company Secretary | 0 | 1973 |
Description
Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline products include eleven clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal, and infectious diseases. Everest Medicines Limited was incorporated in 2017 and is headquartered in Shanghai, China.
